噻吩并[2,3-b]吡嗪-7-胺 | 59944-75-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 噻吩并[2,3-b]吡嗪-7-胺
• 中文别名: 噻吩[2,3并]吡嗪-7-氨
• 英文名称: thieno[2,3-b]pyrazin-7-amine
• 英文别名: thieno[2,3-b]pyrazin-7-ylamine；7-Amino-thieno<2,3-b>pyrazin
• CAS: 59944-75-1
• 化学式: C₆H₅N₃S
• mdl: MFCD08271970
• 分子量: 151.192
• InChiKey: ZRVKSPNBHZCQKY-UHFFFAOYSA-N

物化性质

• 熔点：
  88 °C

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  80
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H312,H315,H319,H332,H335

反应信息

• 作为产物：
  描述：

  7-氨基噻吩并[2,3-b]吡嗪-6-羧酸 在 铜 作用下， 生成 噻吩并[2,3-b]吡嗪-7-胺
  参考文献：
  名称：

  Schneller,S.W. et al., Journal of Heterocyclic Chemistry, 1976, vol. 13, p. 273 - 275

  摘要：

  DOI：

文献信息

• Aromatic amine derivative and use thereof
  申请人：Taniguchi Takahiko

  公开号：US20090325956A1

  公开（公告）日：2009-12-31

  The present invention provides a novel SCD inhibitor. An SCD inhibitor containing a compound represented by the formula [I] wherein ring A is an optionally substituted aromatic ring, ring B is an optionally substituted ring, ring C is an optionally substituted aromatic ring, R is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and X is a spacer having 1 to 5 atoms in the main chain, or a salt thereof, or a prodrug thereof.

  本发明提供了一种新型SCD抑制剂。一种包含由下式[I]表示的化合物的SCD抑制剂 其中环A是可选择取代的芳香环，环B是可选择取代的环，环C是可选择取代的芳香环，R是氢原子，可选择取代的碳氢基团或可选择取代的杂环基团，X是具有主链中1到5个原子的间隔物，或其盐，或其前药。
• [EN] FUSED HETEROCYCLIC COMPOUNDS AS SELECTIVE BMP INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES FUSIONNÉS EN TANT QU'INHIBITEURS SÉLECTIFS DE PROTÉINE MORPHOGÉNÉTIQUE OSSEUSE (BMP)
  申请人：UNIV VANDERBILT

  公开号：WO2018136634A1

  公开（公告）日：2018-07-26

  The present invention provides small molecule inhibitors of BMP signaling that are useful for treating diseases or conditions associated with BMP signaling, including cancers of the central nervous system.

  本发明提供了用于治疗与BMP信号传导相关的疾病或症状，包括中枢神经系统癌症的小分子抑制剂。
• HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS
  申请人：eFFECTOR Therapeutics, Inc.

  公开号：US20170145009A1

  公开（公告）日：2017-05-25

  The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula IA or Formula IB, as well as stereoisomers, tautomers or pharmaceutically acceptable salts thereof. For Formula IA and Formula IB compounds A 1 , A 2 , A 3 , A 4 , W 1 , W 2 , Y, X, R 1 , R 2 , R 3 , R 4a , R 4b , R 5a , R 5b , R 6 , R 7 , R 8 , R 9 , R 9a , R 9b , R 10 and subscript n are as defined in the specification. The inventive Formula IA and Formula IB compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
• US6376488B1
  申请人：——

  公开号：US6376488B1

  公开（公告）日：2002-04-23
• [EN] BENZOXAZINE ALPHA-1 ADRENERGIC COMPOUNDS<br/>[FR] COMPOSES DE BENZOXAZINE ALPHA-1 ADRENERGIQUE
  申请人：ABBOTT LAB

  公开号：WO2002020533A2

  公开（公告）日：2002-03-14

  The present invention relates to compounds having formula I and to pharmaceutically acceptable salts thereof. Compounds of formula I inhibit a1 adrenoreceptors and may be useful for treating benign prostatic hyperplasia (also called benign prostatic hypertrophy) and other urological diseases such as bladder outlet obstruction, neurogenic bladder and gynecological syndromes.